Bridging the gap to therapeutic strategies based on connexin/pannexin biology.

Christian C Naus,Christian Giaume

doi:10.1186/s12967-016-1089-0

Abstract

A unique workshop was recently held focusing on enhancing collaborations leading to identify and update the development of therapeutic strategies targeting connexin/pannexin large pore channels. Basic scientists exploring the functions of these channels in various pathologies gathered together with leading pharma companies which are targeting gap junction proteins for specific therapeutic applications. This highlights how paths of discovery research can converge with therapeutic strategies in innovative ways to enhance target identification and validation.

Highlights

The essential role of gap junction channels and hemichannels in the normal functioning of cells and its relationship to diseases is only beginning to be understood
This study indicates that flecainide improves the pharmacological profile of modafinil, likely through the normalization of gap junctional communication (GJC) in astroglial networks, opening new perspectives in the management of narcolepsy
Summary and future directions Considerable insights continue to emerge regarding the biology of connexins and pannexins, and their possible roles in health and disease

Summary

Introduction

Background The essential role of gap junction channels and hemichannels in the normal functioning of cells and its relationship to diseases is only beginning to be understood. Following an overview presented by Dale Laird (Western University, Ontario, Canada), Paul Lampe (Fred Hutchinson Cancer Research Centre, Seattle, WA, USA) provided insight on the most widely expressed gap junction protein, connexin43 (Cx43), focusing on its phosphorylation at many amino acid residues in the cytoplasmic, C-terminal region [6]. Blocking Cx hemichannel reduces pro-inflammatory mediated events suggesting that specific connexin channel blockers may provide a strategy to reduce skin inflammation.

Results

Conclusion